Trust Co. of Toledo NA OH Reduces Position in AstraZeneca PLC $AZN

Trust Co. of Toledo NA OH decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 9.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,921 shares of the company’s stock after selling 695 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in AstraZeneca were worth $484,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Larson Financial Group LLC boosted its position in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after acquiring an additional 289 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in shares of AstraZeneca during the 1st quarter valued at about $29,000. Costello Asset Management INC acquired a new position in shares of AstraZeneca during the 1st quarter valued at about $29,000. Highline Wealth Partners LLC boosted its position in shares of AstraZeneca by 447.4% during the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock valued at $31,000 after acquiring an additional 340 shares during the last quarter. Finally, Maseco LLP acquired a new position in shares of AstraZeneca during the 2nd quarter valued at about $34,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.6%

NASDAQ AZN opened at $84.53 on Friday. The firm’s 50-day moving average is $79.18 and its two-hundred day moving average is $73.46. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $86.57. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The stock has a market capitalization of $262.16 billion, a P/E ratio of 31.78, a PEG ratio of 1.55 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.08 billion. During the same quarter in the prior year, the company posted $1.24 earnings per share. AstraZeneca’s revenue for the quarter was up 16.1% compared to the same quarter last year. On average, sell-side analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a dividend of $0.505 per share. The ex-dividend date was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s dividend payout ratio is 37.97%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AZN shares. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday. Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.